Huawei Expands AI-Pharma Partnerships Across Drug Development

Shanghai, 27 August 2026 – Huawei is planning deeper collaboration with Chinese pharmaceutical companies as it extends artificial intelligence from drug manufacturing and compound screening into clinical practice and final implementation. The strategy positions the technology group within a fast-developing healthcare market where computing platforms, specialised models and automated laboratories are being used to shorten research timelines and improve productivity.

William Zhang, president of Huawei’s healthcare business unit, said the company expects more partnerships and results to emerge as its medical AI research advances. Existing projects are mainly with domestic drugmakers, while Huawei also has collaborations involving clinical practice in hospitals. The company did not disclose a timetable, investment amount or list of additional partners, leaving the commercial scale of the planned expansion open.